Accumulating evidence from these CVOTs has revealed much promise for GLP-1R agonists and SGLT2 inhibitors, but not DPP4 inhibitors, in terms of improving cardiovascular outcomes in people with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.